Working… Menu

Photodynamic Therapy in Treating Patients With Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01668823
Recruitment Status : Completed
First Posted : August 20, 2012
Last Update Posted : July 31, 2014
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute

Brief Summary:
This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer. Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed.

Condition or disease Intervention/treatment Phase
Adenocarcinoma of the Lung Large Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Squamous Cell Lung Cancer Stage 0 Non-small Cell Lung Cancer Drug: HPPH Drug: photodynamic therapy Procedure: therapeutic bronchoscopy Phase 1

Detailed Description:


I. To determine maximally tolerated light dose (MTID). Identify systemic and normal tissue toxicity using 2-[hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) for photodynamic therapy in patients with bronchogenic carcinoma-in-situ (CIS) or microinvasive carcinoma.


I. To study tumor response in patients with bronchogenic carcinoma-in-situ (CIS) or bronchogenic microinvasive carcinoma.

OUTLINE: This is a dose-escalation study.

Patients receive HPPH intravenously (IV) over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.

After completion of study treatment, patients are followed up at 4-6 weeks, 6 months, and then periodically for at least 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-small Cell Carcinoma in Situ or Non-small Cell Microinvasive Carcinoma. A Dose Ranging Study
Study Start Date : February 2004
Actual Primary Completion Date : June 2013
Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment (PDT using HPPH)
Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
Drug: HPPH
Given IV
Other Name: Photochlor

Drug: photodynamic therapy
Undergo photodynamic therapy with HPPH
Other Names:
  • Light Infusion Therapy™
  • PDT
  • therapy, photodynamic

Procedure: therapeutic bronchoscopy
Undergo therapeutic bronchoscopy for endoscopic debridement

Primary Outcome Measures :
  1. MTID [ Time Frame: Up to 2 years ]
    Defined as the dose at which =< 1 out of 6 patients experiences dose-limiting toxicity.

  2. Systemic toxicity according to NCI Common Toxicity Criteria version 2 [ Time Frame: Up to 6 months ]
  3. PDT-related normal tissue toxicity [ Time Frame: Up to 6 months ]
    Assessed by a scale with grades 0-3 being acceptable, grade 4 being unacceptable, and grade 5 being stopping study.

Secondary Outcome Measures :
  1. Objective tumor response [ Time Frame: Up to 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with biopsy confirmed carcinoma-in-situ (CIS) or microinvasive lung cancer
  • Patients may have squamous cell carcinoma, adenocarcinoma, or large cell carcinoma
  • Patients may have received prior therapy for lung cancer of any type, e.g. chemotherapy, radiation therapy
  • Patients must have no contraindications for bronchoscopy
  • Female patients must not be pregnant and must be practicing a medically acceptable form of birth control, be sterile or post-menopausal
  • Patients must have a Karnofsky scale 50 or above (Eastern Cooperative Oncology Group [ECOG] 0-2)
  • Patients must sign an Informed Consent according to Food and Drug Administration (FDA) guidelines acceptable to the Roswell Park Cancer Institute (RPCI) Institutional Review Board (IRB)
  • Patients with underlying lung disease must be judged (by the principal investigator) able to with stand mucous/debris formation at the site of treatment
  • Definition of CIS or microinvasive lung cancer for this protocol: the lesion will be radiographically occult and not definable by conventional computed tomography (CT) of the chest; the lesion may or may not be invisible on white light bronchoscopy, but is definable and photographable on lung imaging fluorescence endoscope (LIFE) bronchoscopy; biopsies of the lesion must indicate no evidence of invasion beyond cartilage on histopathology; the lesion may, however, be invasive through the basement membrane (microinvasive carcinoma)

Exclusion Criteria:

  • Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds
  • White blood cells (WBC) < 4000
  • Platelet count < 100,000
  • Prothrombin time exceeding 1.5 times the upper normal limit
  • Total serum bilirubin > 3.0 mg/dl
  • Serum creatinine > 3.0 mg/dl
  • Alkaline phosphatase (hepatic) or serum glutamic oxaloacetic transaminase (SGOT) > 3 times the upper normal limit
  • Severe chronic obstructive pulmonary disease (COPD) that would in the opinion of the investigator preclude multiple bronchoscopies or partial central airway obstruction from mucous/debris formation
  • Any evidence of worsening pulmonary symptoms or COPD exacerbation
  • Evidence of major pulmonary vessel encasement on CT scan of the chest
  • Myocardial infarction (Ml) or unstable angina in the previous 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01668823

Layout table for location information
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Samjot Dhillon Roswell Park Cancer Institute
Layout table for additonal information
Responsible Party: Roswell Park Cancer Institute Identifier: NCT01668823    
Other Study ID Numbers: I 05903
NCI-2010-02114 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: August 20, 2012    Key Record Dates
Last Update Posted: July 31, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma of Lung
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type